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Objectives. The aim of this study was to assess the immediate
and short-term results of anterograde catheter closure of a
moderate- to large-sized patent ductus arteriosus (PDA) using the
new self-expandable, respositionable Amplatzer duct occluder
(ADO) device.
Background. Transcatheter closure of a PDA using devices or
coils is technically challenging and may be accompanied by a 38%
incidence of residual shunts.
Methods. Twenty-four patients (6 male, 18 female) underwent
attempted transcatheter closure of a PDA using the ADO at a
median age of 3.8 years (range 0.4 to 48) and a median weight of
15.5 kg (range 6 to 70). The mean PDA diameter at its narrowest
segment was 3.7 6 1.5 mm. A 6F long sheath was used for delivery
of the ADO. Follow-up evaluation was performed with color flow
mapping of the main pulmonary artery within 24 h and at 1 and
3 months after closure.
Results. Twenty three of the 24 patients had successful device
placement. Angiography showed that 7 patients had complete
immediate closure, 14 had a trace shunt (foaming through the
device with no jet), and 2 had a small residual shunt (with a jet).
Within 24 h, color Doppler revealed complete closure in all
patients. The unsuccessful attempt was during an initial trial with
a prototype that has been modified. The median fluoroscopy time
was 13.5 min (range 6.3 to 47). All patients were discharged home
the next day. There were no complications. Of the 23 patients, 21
completed the 1-month follow-up, all (95% confidence interval
[CI] 86% to 100%) with complete closure, and 18 of 23 patients
completed the 3-month follow-up, also all (95% CI 83% to 100%)
with complete closure.
Conclusions. Anterograde transcatheter closure using the new
ADO is an effective therapy for patients with a PDA diameter up
to 6 mm. Further clinical trials are underway.
(J Am Coll Cardiol 1998;31:878–82)
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The Rashkind, buttoned, Botalloocluder devices and coils have
been used extensively for transcatheter closure of a patent
ductus arteriosus (PDA) with variable degrees of successful
deployment and an incidence of residual shunting varying
between 3% and 38% (1–9). Furthermore, some of the devices
require large delivery catheters, limiting their use in small
infants, and the use of these devices and coils is technically
challenging, especially for large PDAs. Recently, Sharafuddin
et al. (10) reported on the use of a new self-expandable device
(Amplatzer duct occluder [ADO]) to close surgically created
aortopulmonary shunts in a canine model with very encourag-
ing results. In the present report, we describe the immediate
and short-term results using the ADO to close moderate- to
large-sized PDAs.
Methods
Patients. From September 1996 to June 1997, 24 patients
(18 female, 6 male) underwent attempted transcatheter closure
of a PDA as an alternative to standard surgical ligation or the
use of other devices. Informed consent was obtained from all
patients. All patients had clinical and echocardiographic find-
ings of a PDA. The patients median age was 3.8 years (range
0.4 to 48), and their weights ranged from 6 to 70 kg (median
15.5 kg). All patients were asymptomatic, except for Patient 22,
who had failure to thrive and pulmonary artery hypertension
(mean 46 mm Hg) from the large PDA (5.7 mm). All patients
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had left atrial and ventricular volume overload documented by
echocardiography and angiography.
ADO device. The Amplatzer duct occluder (AGA Medical
Corporation, Golden Valley, MN) is a self-expandable,
mushroom-shaped device made from a 0.004-in. thick Nitinol
wire mesh (a thin retention disk, 4 mm larger in size than the
diameter of the device ensures secure positioning in the mouth
of the PDA). The PDA is closed by the induction of throm-
bosis, which is accomplished by polyester fibers sewn securely
into the device. Platinum marker bands are applied to the wire
ends and laser welded. The shape is then formed by heat
treatment. After cooling, a stainless steel sleeve with a female
thread is welded to the marker band using advanced laser
technology, Figure 1 demonstrates the device currently under
clinical evaluation with the delivery system. All devices are
cone-shaped and 7 mm in length, with a recessed screw, sizes
are given from the larger to the smaller diameter. The delivery
system consists of a delivery cable, long Mullins-type sheath,
loader and pin vise (Fig. 1).
Closure protocol. Figure 2 demonstrates the steps of the
procedure for the implantation of the ADO. All patients
underwent routine right and left heart catheterization using a
4F or 5F sheath in the femoral artery and a 6F sheath in the
femoral vein. Heparin was used according to operator prefer-
ences. A biplane anteroposterior and lateral descending aor-
togram was performed to evaluate the size, position and shape
of the ductus. A 5F or 6F multipurpose catheter was advanced
from the venous side into the PDA and placed in the descend-
ing aorta. This catheter was exchanged for the delivery sheath
(6F) over a 0.035-in. exchange guidewire and the dilator was
removed, leaving the sheath in the descending aorta.
The delivery cable was passed through the loader and the
proper size occlusion device ($1 to 2 mm larger than the
narrowest size of the PDA) was screwed clockwise into the tip
of the delivery cable. The device and the loader were immersed
in saline solution as the ADO was pulled into the loader. The
loader was introduced into the delivery sheath and without
rotation the device was advanced into the descending aorta.
The sheath was retracted until the retention disk was opened in
the proximal descending aorta. The sheath with the delivery
cable in it were pulled back as one unit until the retention disk
was snug against the aortic end of the ampulla. While main-
taining tension on the delivery cable, the introducing sheath
was withdrawn into the pulmonary artery to deploy the tubular
frame of the prosthesis into the PDA, similar in a way to
deployment of a self-expandable stent. With the device still
attached to the cable, a descending aortogram was performed
in the lateral projection to confirm device position. If there was
device malposition, the device could be retracted back inside
the delivery sheath. Once proper device position was con-
firmed, the device was released by turning the cable counter-
clockwise using the pin vise. A repeat descending aortogram
Figure 1. Amplatzer Duct Occluder and delivery system. A, Schematic
representation of the device. Note the cone shape and the various
measurements; for example, for the 10-mm, 8-mm device, the distance
between the two long curved arrows is 8 mm; the distance between the
two short arrows is 10 mm; and the distance between the long straight
arrow (retention disk) and the long curved arrow is always 7 mm for all
devices. B, Closeup view of the device attached to the delivery cable by
a microscrew. C, Entire delivery system with the device.
Abbreviations and Acronyms
ADO 5 Amplatzer Duct Occluder
CI 5 confidence interval
PDA 5 patent ductus arteriosus
Qp/Qs 5 pulmonary/systemic flow ratio
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was performed 10 minutes after the release to assess the
degree of residual shunt.
Within 24 h, chest radiographs in the posteroanterior and
lateral positions were obtained to assess device position, and
each patient underwent a complete two-dimensional echocar-
diographic study and color flow mapping and Doppler inter-
rogation using commercially available machines. At 1 and 3
months after closure, repeat echocardiography looking for
residual ductal flow in the main pulmonary artery, left pulmo-
Figure 2. Still frames in the lateral projection demonstrating the steps
of closure technique using the ADO in a 1.3-year old, 7.5-kg infant
(Patient 22). A, Descending aortic angiogram reveals a large PDA
measuring 5.7 mm in diameter. B, The retention disk is opened in the
proximal aorta, opposite the ampulla (arrow). C, The rest of the device
is opened in the PDA. D, Repeat descending aortogram with the
device still attached to the delivery cable, confirming a good position,
with no obstruction to the aorta. E, Descending aortogram 10 min after
release of the device, revealing a good device position with trace
residual shunt. F, Descending aortogram 1 month after closure,
revealing complete closure with good device position.
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nary artery stenosis or aortic obstruction was performed fol-
lowing previously described techniques (11,12). Chest X-ray
films in posteroanterior projections were obtained to check for
wire fractures during the same follow-up examinations.
Statistical analysis. Results are expressed as mean value 6
SD or median and range; 95% confidence intervals were
calculated for the 1- and 3-month follow-up periods.
Results
Patients. The clinical data of the 24 patients are shown in
Table 1. The mean PDA diameter was 3.7 6 1.5 mm, and the
median pulmonary/systemic flow ratio (Qp/Qs) was 2.2 (range
1.6 to 11). According to the classification adopted by
Krichenko et al. (13), 22 patients had PDA type A, and 2 had
type E. All closures were achieved from the venous side. In 23
patients the device was placed successfully in the PDA. One
patient (Patient 7), a 9-kg infant with a PDA measuring 1.2 mm
at its narrowest point with a short ampulla, initially underwent
an attempt at deploying a device 6–4 mm in diameter and
10 mm in length. Deploying the retention disk in the aortic end
resulted in obstruction of more than half the aorta. Therefore,
the device was retracted inside the delivery sheath; placement
of a coil resulted in complete closure. Subsequent to this
patient, all devices were modified to make their length shorter
(7 mm), and the screw was recessed inside the disk (Fig. 1).
Eight patients had immediate angiographic closure of the
PDA, including the single patient who received a coil; 14
patients had trace angiographic residual shunt (7) with “foam-
ing” through the device and no contrast jet; and 2 patients had
small residual shunt with a contrast jet through the device. One
patient (Patient 22) with significant pulmonary artery hyper-
tension (mean 46 mm Hg) had immediate improvement, with
reduction of the pulmonary artery mean pressure to
24 mm Hg. The median fluoroscopy time was 13.5 min (range
6.3 to 47), and the median total procedure time was 60 min
(range 36 to 185). The longest fluoroscopy and procedure
times were in two patients (Patients 2 and 11). Patient 2
underwent the procedure during our early learning experience;
in Patient 11, both the retention disk and the tubular part of
the device were deployed inside the PDA, with some difficulty
in repositioning the device precisely. There were no complica-
tions during or after the procedure.
There was no evidence of obstruction of the left pulmonary
artery or the descending aorta confirmed on the following day
and on follow-up by Doppler interrogation. No patient re-
quired blood transfusion. There were no femoral arterial or
venous complications. All patients were discharged home the
day after the catheterization procedure.
Table 1. Clinical and Closure Data for All Patients
Pt No./
Age (yr)
Weight
(kg) Qp/Qs
PDA Diam
(mm) Type
Device
Size* (mm)
Result
FT
(min)
PT
(min)Immed 1 day 1 mo 3 mo
1/2.5 11 1.7 2.4 A 6 TS C C C 8.0 55
2/15 41 2.6 4.9 A 6 TS C C C 30 70
3/48 55.1 1.6 4.0 A 6 C C C C 24 60
4/1.6 12.4 . 4.0 5.5 A 8 SS C C C 22.6 75
5/5.2 20 2.2 3.1 A 5 C C C C 12 80
6/0.9 7.2 NA 3.3 E 6 C C C C 16 54
7/1.4 9.0 NA 1.2 A Coil C C C C 18 56
8/5.0 17 1.8 2.0 A 7 TS C C C 11 45
9/1.3 8.4 NA 6.0 E 8 SS C C C 8.0 60
10/1.5 8.0 2.5 5.1 A 7 TS C C C 19 95
11/5.7 21 2.9 2.0 A 6 TS C C C 47 185
12/29.3 58 2.1 3.8 A 7 TS C C C 22 180
13/44 70 2.0 3.0 A 7 C C C C 11 45
14/25.2 56 2.6 4.0 A 8 TS C C C 13 60
15/6.5 26 2.6 2.3 A 5 TS C C C 8.0 55
16/0.6 7.1 NA 5.0 A 7 TS C C C 10 87
17/2.8 14 1.9 2.8 A 6 TS C C C 10 60
18/2.2 12 1.9 2.7 A 4 TS C C C 18 65
19/0.4 6.0 1.8 5.5 A 6 TS C C 10 50
20/2.0 10 2.5 1.9 A 5 TS C C 12 65
21/4.8 21 2.6 2.3 A 7 C C C 14 45
22/1.3 7.5 3.5 5.7 A 8 TS C C 15 65
23/14 37 1.8 5.5 A 8 C C 6.3 36
24/33 62 1.6 5.0 A 6 C C 24.4 90
*See Figure 1 for device size measurement. C 5 closure; Coil 5 procedure failed for device implantation, a coil was
implanted instead; Diam 5 diameter; FT 5 fluoroscopy time; Immed 5 immediately at the end of procedure; NA 5 not
available; PDA 5 patent ductus arteriosus; PT 5 procedure time; Pt 5 patient; Qp/Qs 5 pulmonary/systemic flow ratio;
SS 5 small shunt; TS 5 trace shunt by angiography (7).
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Follow-up. At 24 h, all 23 patients had complete closure of
their PDAs on color Doppler echocardiography. Of the 23
patients, 21 completed the 1-month follow-up period, all (95%
confidence interval [CI] 86% to 100%) with complete closure,
and 18 of 23 patients completed the 3-month follow-up, all
(95% CI 83% to 100%) with complete closure and no evidence
of device migration, recanalization, thromboembolic episodes,
endocarditis, wire fracture or clinical evidence of hemolysis.
Discussion
The feasibility of nonsurgical closure of the PDA was
demonstrated when Porstmann et al. (14) in 1967 reported
closing a PDA with an Ivalon plug in a 17-year old boy without
thoracotomy. Subsequently, a number of devices and coils have
been used for catheter closure of PDA with varying degrees of
success (1–9). The major drawbacks of these devices and coils
are the high incidence of residual shunt, the sometimes
complex delivery systems and their unsuitability for larger
PDAs.
In this study, we report our initial human experience using
a different new device to close PDAs #6 mm in diameter. We
performed the closures from the venous side in all patients,
using 6F catheters. The venous route has several advantages,
including confirmation of PDA position before device release
because the arterial catheter can be used for injection of
contrast, avoidance of a large sheath in the femoral artery and
the potential application of this technique to the very young
infant who has PDA. Although we did not encounter all the
angiographic types of PDA, we believe that such PDAs will be
easily amenable to closure with this device. Further clinical
testing is necessary to determine any potential size and angio-
graphic shape limitations of this device. Although most pa-
tients had a residual shunt at the end of the procedure, none
had a detectable residual shunt by color flow mapping within
24 h of implantation, stressing the advantage of the plug type
of design of the device for closing PDAs. Although most
procedures were performed under anesthesia and patients
were admitted to the hospital for one night, we believe that
because of the small size sheath, the closure can be safely
performed as an outpatient procedure under local anesthesia
and heavy sedation. On the basis of our preliminary work, the
devices will be available in a kit that contains three different
sizes (10–8, 8–6 and 6–4 mm) to cover the whole range of
PDA sizes.
Conclusions. The ADO is safe and effective in closing
PDAs in most patients with a PDA #6 mm in diameter.
Further clinical trials are underway to assess any potential size
or shape limitations before the widespread use of this device.
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